
Apollo Hospitals has reported a strong performance for the fourth quarter of FY25, with its net profit rising by 53.5% year-on-year to ₹390 crore. The profit before tax grew by 40% to ₹515.5 crore, while EBITDA increased by 20% to ₹769.9 crore compared to ₹640.5 crore in the same period last year.
The EBITDA margin also improved to 13.8% from 13% in Q4 FY24. Revenue from operations grew 13% year-on-year, with healthcare services contributing ₹2,822 crore (up 10%), Apollo Health and Lifestyle (AHLL) generating ₹394 crore (up 11%), and Apollo HealthCo bringing in ₹2,376.3 crore (up 17%). As of March 31, 2025, Apollo Hospitals operated 8,025 beds (excluding AHLL and managed beds), with an overall occupancy rate of 67%, up from 65% last year.

Read More: NBCC Announces 29% Surge in Q4 Profit, Reaches ₹176 Crore..
For the full year FY25, Apollo’s net profit rose by 60.9% to ₹1,445.9 crore, while total revenue increased by 14.3% to ₹21,794 crore. Dr. Prathap C Reddy, Chairman of Apollo Hospitals, called FY25 a defining year, highlighting that the group crossed ₹20,000 crore in total revenue and ₹11,000 crore from healthcare services alone.
He emphasized Apollo’s focus on preventive healthcare and announced plans to launch global wellness programs under Apollo ProHealth. Looking ahead, the company plans to open new hospitals in Pune, Kolkata, Hyderabad, Bangalore, and Delhi NCR. Over the next five years, Apollo will invest more than ₹8,000 crore to add over 4,300 beds, with 2,000 already in progress.
Also See: Bajaj Auto’s March Sales Climb to Rs 12,147.97 Cr, Here’s What You Need to Know
In other developments, Apollo Pharmacies has expanded to over 6,600 stores, and Apollo 24/7 has started distributing insurance products to increase access to healthcare. The company’s board has recommended a final dividend of ₹10 per equity share (face value ₹5), with a record date set for August 19, 2025. If approved, the dividend will be paid by September 10, 2025. Additionally, Apollo will purchase a 2.53-acre land parcel in Sarjapur, Bengaluru, to build a 500-bed multi-specialty hospital at an estimated cost of ₹944 crore. It also plans to acquire and upgrade an existing 200-bed hospital nearby for ₹285 crore. Apollo continues to expand its presence across hospitals, pharmacies, telemedicine, insurance, medical education, and global consultancy. Despite the strong financial results, Apollo’s stock closed down 0.68% at ₹6,878.20 on the BSE.